Phase II Trial of Combination Pemetrexed (Alimta) and Carboplatin (Paraplatin) in Platinum Sensitive Recurrent Ovarian, Primary Peritoneal, and Fallopian Tube Carcinoma
||Aliza Leiser, M.D.
| Time frame of study:
|Location of Study:
Beth Israel Medical Center
St.Luke's-Roosevelt Hospital Center
Continuum Cancer Research Program
Pemetrexed is a promising chemotherapy drug for ovarian cancer treatment. Carboplatin is the standard of care chemotherapy drug in ovarian cancer. It has demonstrated antitumor activity when combined with Pemetrexed in other solid tumors. A Phase II study in 2008 showed that combination of Carboplatin and Pemetrexed in subjects with ovarian cancer had a good response rate (over 55%). We therefore propose to study the effect of Pemetrexed plus Carboplatin in the treatment of recurrent ovarian cancers in an effort to improve response rates among these subjects.
- Histologically or cytologically proven (by observing cells), previously treated, epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer,
- Previously treated for ovarian cancer with a taxane (e.g., docetaxel) and platinum (e.g., cisplatin) based regimen
- No presence of active cancer other than that described in the inclusion criteria,
- No uncontrolled intercurrent illness not limited to infection, symptomatic congestive heart failure, or unstable angina pectoris, or cardiac arrhythmia,
- No history of severe allergy to platinum compounds.
Please call for more information.